 Shares of electroCore Inc. more than doubled up 155 on very heavy volume in afternoon trading Monday, after the bioelectronic medicine company said it was issued an emergency use authorization EUA by the Food and Drug Administration OKing the use of its gammaCore Sapphire CV to help in the treatment of COVID-19 patients. Trading volume soared to 136.7 million shares, enough to make the stock the most actively traded on the Nasdaq exchange, and compared with the full-day average of about 1.1 million shares. Needless to say, we are very pleased to have received this EUA, and we intend work vigorously to make this novel therapy available to physicians treating known or suspected COVID 19 patients who are experiencing exacerbation of asthma-related breathing difficulty, said Chief Executive Dan Goldberger. The stock has rallied 36 year to date, while the SP; 500 is little changed. 